Successful Business Combination of Alps Group and Globalink Investment
Alps Group Inc, the parent company of Alps Life Sciences, has reached a significant milestone with the completion of its business combination with Globalink Investment Inc, a special purpose acquisition company. This merger unites two innovative firms committed to advancing healthcare through biotechnology.
Details of the Business Combination
The merger was executed following an Amended and Restated Merger Agreement, detailing the terms as agreed upon by both parties. The two-step process involved a Redomestication Merger where Globalink merged into Alps Group, leading to Alps Group as the surviving entity. Consequently, the Acquisition Merger allowed Merger Sub to combine effectively with Alps Holdco, making it a wholly owned subsidiary of Alps Group.
Trading Commencement on Nasdaq
As a result of the merger, Alps Group Inc will begin trading on the Nasdaq under the symbol "ALPS". This is a pivotal moment for the firm as it aims to leverage the expanded market presence and growth opportunities associated with being a publicly traded company. The market anticipates the combined entity will showcase an estimated enterprise value of around US$1.6 billion.
Leadership Insights
Findings from Dr. Tham Seng Kong
Dr. Tham Seng Kong, who will serve as the Chief Executive Officer and Chairman of the Board for Alps Group, expressed enthusiasm about the new venture. He noted this listing as a critical step in their journey, enabling them to broaden their reach and enhance their mission to make advanced healthcare solutions accessible to all. He emphasized the organization's commitment to innovative research in genomics and personalized medicine.
Feedback from Mr. Say Leong Lim
Mr. Say Leong Lim, previously the CEO of Globalink, shared his satisfaction with the completion of the business combination. He believes this new phase will create immense value for shareholders and facilitate growth initiatives for Alps Group. He extended gratitude to the teams and partners involved throughout this process.
Investment and Growth Strategy
In conjunction with the merger, Alps Group has entered into subscription agreements with certain investors to raise approximately US$3.1 million. This PIPE investment supports the company’s efforts in expanding its strategy and maintaining adequate working capital, which is crucial for ongoing innovation and development in biotechnology.
Commitment to a Collaborative Ecosystem
Dr. Tham highlighted the launch of their BioValley initiative, a cutting-edge hub designed to foster a supportive ecosystem for innovation in biotech, aligning researchers, investors, and patients. This initiative aims to elevate the capacity for high-tech startups in the region, reflecting Malaysia's potential to compete in the global biotech landscape.
Looking Ahead for Alps Group
The completion of this merger signifies not just a change in company structure but an entire new approach to how Alps Group envisions the future of healthcare. The partners are dedicated to dismantling barriers in access to innovative therapies and ensuring that cutting-edge healthcare solutions reach those in need.
Frequently Asked Questions
What is the significance of the merger between Alps Group and Globalink?
This merger allows Alps Group to gain a wider platform for its biotechnology innovations and enhances its market presence.
When will Alps Group's shares start trading?
The ordinary shares will commence trading on the Nasdaq under the ticker symbol "ALPS" starting on October 31, 2025.
Who will lead the newly formed Alps Group?
Dr. Tham Seng Kong will be the Chief Executive Officer and Chairman of the Board of Directors for Alps Group.
What is the BioValley initiative?
The BioValley initiative is a new program aimed at fostering innovation in the biotechnology sector, providing resources for startups and researchers.
How much investment has been secured by Alps Group?
Alps Group secured approximately US$3.1 million through subscription agreements with PIPE investors to support its growth strategy.
